Clinical outcomes and genomic alterations in patients with metastatic malignant phyllodes tumors
AI therapy is useful for advanced or recurrent MPTs. The observed clinical benefit of pazopanib in a patient with FGFR1 N546K-mutated MPT suggests that FGFR1 kinase domain mutations may be a relevant factor in responsiveness of FGFR1-targeted therapy. Further data accumulation is warranted.
Authors
- Shuji Arita
- Kotoe Oshima (ORCID: https://orcid.org/0000-0003-1491-9811)
- Kenta Nio
- Kenji Tsuchihashi (ORCID: https://orcid.org/0000-0002-9014-6382)
- Koji Ide
- Hiroshi Ariyama (ORCID: https://orcid.org/0000-0002-8374-5045)
- Wataru Kusano
- Mamoru Ito (ORCID: https://orcid.org/0000-0002-9300-825X)
- Aya Takigawa
- Hirofumi Ohmura (ORCID: https://orcid.org/0000-0003-4650-9120)
- Hitoshi Kusaba (ORCID: https://orcid.org/0000-0002-2949-5970)
- Eishi Baba (ORCID: https://orcid.org/0000-0001-9428-6772)
- Miyuki Kuwayama
- Taichi Isobe (ORCID: https://orcid.org/0000-0001-5686-1940)
- Yasuhiro Doi (ORCID: https://orcid.org/0000-0002-4644-7559)
- Koichi Akashi (ORCID: https://orcid.org/0000-0001-7763-5723)
- Toshihiro Yamaguchi (ORCID: https://orcid.org/0000-0002-5458-5345)
- Shingo Tamura
Institutions
- Kyushu University (JP)
- National Kyushu Medical Center (JP)
- Shizuoka Cancer Center (JP)
- Kyushu University Hospital (JP)
- Hamanomachi Hospital (JP)
- Miyazaki Prefectural Hospital (JP)
- Kitakyushu Municipal Medical Center (JP)
- Miyazaki Welfare Medical College (JP)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2025-11-05
- DOI
- https://doi.org/10.1093/jjco/hyaf169
- Primary Topic
- Fibroblast Growth Factor Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00